Pfizer reported Q1 2025 revenue of $13.7B (-7.8% YoY), missed analyst consensus of $13.9B by $204.7M. Diluted EPS came in at $0.92 (+12.2% YoY), beat the $0.67 consensus by $0.25. Pfizer reports across 2 business segments, led by Biopharmaceutical Products and Biosimilars.
Trailing eight quarters through Q1 2025
Common questions about Pfizer's Q1 2025 earnings report.
Pfizer (PFE) reported Q1 2025 earnings on April 29, 2025 before market open.
Pfizer reported revenue of $13.7B and diluted EPS of $0.92 for Q1 2025.
Revenue missed the consensus estimate of $13.9B by $204.7M. EPS beat the consensus estimate of $0.67 by $0.25.
Compared to the same quarter a year prior, revenue declined 7.8% from $14.9B a year earlier and diluted EPS grew 12.2% from $0.82.
You can read the 10-Q periodic report (0000078003-25-000114) directly on SEC EDGAR. The filing index links above go to sec.gov.